Organization
Orum Therapeutics
1 clinical trial
5 abstracts
Clinical trial
Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-04-01
Abstract
Adopting combination machine learning models could reduce hospital length of stay for oncology patients.Org: Integra Connect, West Palm Beach, Flare Therapeutics, Bengaluru, Indiana University School of Medicine,
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay.Org: Precede Biosciences, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings,
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, Il-Yang Pharmaceuticals, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle Gummy Company,
Abstract
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, NEXT Oncology - Virginia Cancer Specialists, University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute,